TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22506884

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to classical music through computer speakers during injection)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (no music during injection)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study: 15987865

Group type: EXPERIMENTAL
Intervention: Dietary supplements (vitamins, minerals, and nutraceuticals)
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Nonsupplement users
Number of subjects: 1776

Group type: EXPERIMENTAL
Intervention: Dietary supplements
Number of subjects: 1776
Study: 12099389

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (Genotropin) at a dose of 0.2 IU/kg/day for 2 years (Group 1)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment for one year after the initial trial (Group 2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (Group 2) without treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Follow-up after discontinuation of GH therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of recent heights between GH-treated group and control group at final examination
Number of subjects: 26
Study: 10541761

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day)
Number of subjects: 30
Study: 7546498

Group type: EXPERIMENTAL
Intervention: 5 mg isradipine SRO at 08:00
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg isradipine SRO at 20:00
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2182350

Group type: EXPERIMENTAL
Intervention: Daily-wear hard (DWH) PMMA contact lens
Number of subjects: 110

Group type: COMPARATOR
Intervention: Extended-wear (XW) lenses
Number of subjects: 110
Study: 43950

Group type: EXPERIMENTAL
Intervention: 40 or 100 mg betadrenol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Benzodiazepine derivative
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28195973

Group type: EXPERIMENTAL
Intervention: P24 (24 hours recovery)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: P48 (48 hours recovery)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: P72 (72 hours recovery)
Number of subjects: 16
Study: 28618005

Group type: EXPERIMENTAL
Intervention: Lanabecestat 15 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lanabecestat 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lanabecestat (various doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lanabecestat
Number of subjects: 40
Study: 25243731

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 32
Study: 23534542

Group type: EXPERIMENTAL
Intervention: Miravirsen 3 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Miravirsen 5 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Miravirsen 7 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21393207

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ezetimibe glucuronide
Number of subjects: 20
Study: 18640172

Group type: EXPERIMENTAL
Intervention: Electrically heated cigarette smoking system (EHCSS, Series K)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional cigarette (CC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-smoking
Number of subjects: 100
Study: 16519546

Group type: EXPERIMENTAL
Intervention: Extended adjuvant letrozole (2.5 mg/day)
Number of subjects: 5187

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 5187
Study: 12652495

Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adjunctive abciximab
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Subgroup of 109 patients with single-vessel stenting of type A/B1 lesions
Number of subjects: 300
Study: 11147612

Group type: EXPERIMENTAL
Intervention: Dual screen group (sputum cytology + chest X-rays)
Number of subjects: 10040

Group type: COMPARATOR
Intervention: X-ray only group (annual chest X-rays)
Number of subjects: 10040
Study: 9384206

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Baseline FFQ
Number of subjects: 1015
Study: 1526558

Group type: EXPERIMENTAL
Intervention: 7.2% glucose polymer (GP) electrolyte beverage
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tap water (TW)
Number of subjects: 48
Study: 4001757

Group type: EXPERIMENTAL
Intervention: HR-6 containing adenosine triphosphate (three concentrations)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HR-6 containing adenosine triphosphate (average of both sides)
Number of subjects: 16
Study: 30101300

Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (>/=140 mmHg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: High diastolic blood pressure (>/=90 mmHg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Low systolic blood pressure (<120 mmHg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Low diastolic blood pressure (<80 mmHg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Higher heart rates (>/=80 per minute)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Higher pulse pressures (>/=80 mmHg)
Number of subjects: 16485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Long-acting beta agonist
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Combination of long-acting beta agonist and inhaled corticosteroid
Number of subjects: 16485
Study: 26577795

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 309
Study: 24837064

Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction (VRD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnotic Analgesia (HA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HA + VRD
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Treatment Control
Number of subjects: 0
Study: 23170866

Group type: EXPERIMENTAL
Intervention: Psychodramatic group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Analytic group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 20646599

Group type: EXPERIMENTAL
Intervention: PSV in spine position (PSV-SP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PSV in prone position (PSV-PP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NAVA in spine position (NAVA-SP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NAVA in prone position (NAVA-PP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NAVA-PP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NAVA (both positions)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PRVC-base
Number of subjects: 15
Study: 18700689

Group type: EXPERIMENTAL
Intervention: omega 3 fatty acid enhanced supplement with a high ratio of omega3/omega6
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: omega 3 fatty acid enhanced supplement with a low ratio of omega3/omega6
Number of subjects: 65
Study: 15971400

Group type: EXPERIMENTAL
Intervention: 9HR regimen
Number of subjects: 137

Group type: COMPARATOR
Intervention: 2HRZ3/4RH2 regimen
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy
Number of subjects: 137
Study: 12418497

Group type: EXPERIMENTAL
Intervention: 800 mg SAMe
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10479180

Group type: EXPERIMENTAL
Intervention: DTaP-PRP-T-HB
Number of subjects: 0
Study: 8804805

Group type: EXPERIMENTAL
Intervention: 200 mg RU486
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 400 mg RU486
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 600 mg RU486
Number of subjects: 39
Study: 2010562

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam (15 mg)
Number of subjects: 0
Study: 6926651

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with infant during the first hour after birth
Number of subjects: 20
Study: 31804580

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 47
Study: 27743941

Group type: EXPERIMENTAL
Intervention: levodopa (100mg) and carbidopa (25mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 26047420

Group type: EXPERIMENTAL
Intervention: High-definition fiber tractography and diffusion connectometry analysis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Diffusion connectometry analysis
Number of subjects: 3
Study: 23636794

Group type: EXPERIMENTAL
Intervention: Cryotherapy (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No cryotherapy (Control group, n=50)
Number of subjects: 100
Study: 22072548

Group type: EXPERIMENTAL
Intervention: G‐CSF/DXM (lenograstim 6 μg/kg plus 8‐mg DXM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: G‐CSF/placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: G‐CSF/DXM
Number of subjects: 26
Study: 19304422

Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: HIV-negative women
Number of subjects: 939
Study: 16969894

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drop-out model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian framework with Markov chain Monte Carlo methods
Number of subjects: 0
Study: 15512813

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b, three times a week for 1 year
Number of subjects: 384

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 384
Study: 11232001

Group type: EXPERIMENTAL
Intervention: Exercise (continuous cycle ergometry at approximately 80% of predetermined maximal oxygen uptake for 20 min)
Number of subjects: 17
Study: 7851520

Group type: EXPERIMENTAL
Intervention: Patients with unilateral vestibular deafferentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 2768569

Group type: EXPERIMENTAL
Intervention: Hydrocolloid membrane treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 7
Study: 5411446

Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 13
Study: 31622421

Group type: EXPERIMENTAL
Intervention: Nifty cup
Number of subjects: 237
Study: 29733403

Group type: EXPERIMENTAL
Intervention: Weekly supplementation (60 mg iron and 2.8 mg folic acid)
Number of subjects: 1959

Group type: COMPARATOR
Intervention: 2.8 mg folic acid (Control)
Number of subjects: 1959
Study: 27684871

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) with 0.2% ropivacaine (40 mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-FICB (control group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: FICB
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-FICB
Number of subjects: 22
Study: 25367207

Group type: EXPERIMENTAL
Intervention: Nonselective β‐blocker propranolol (30 μg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Selective β1‐blocker metoprolol (40 μg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: α‐blocker phentolamine (3 mg) after PCI
Number of subjects: 43
Study: 21963235

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 20974318

Group type: EXPERIMENTAL
Intervention: Acarbose 150 mg/d
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 18515694

Group type: COMPARATOR
Intervention: Continuation/maintenance nortriptyline
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined continuation/maintenance ECT plus nortriptyline
Number of subjects: 33
Study: 15782623

Group type: COMPARATOR
Intervention: Interferon alfa-2b at 6MIUs.c./three-times-weekly (group A)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Interferon alfa-2b at 3MIUs.c./daily (group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Peg-interferon alfa-2b 1.5mcg/Kg s.c./once-weekly (group C)
Number of subjects: 78
Study: 11556733

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 3 cmH2O
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 3 cmH2O with PEEP of 3 cmH2O
Number of subjects: 19
Study: 9812658

Group type: EXPERIMENTAL
Intervention: Biminkang mixture
Number of subjects: 216

Group type: COMPARATOR
Intervention: Biyankang (control)
Number of subjects: 216
Study: 7954244

Group type: EXPERIMENTAL
Intervention: Low dose (48.0 Gy or 54.4 Gy)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Intermediate dose (64.8 Gy or 72.0 Gy)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: High dose (76.8 Gy or 81.4 Gy)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Low vs. Intermediate dose
Number of subjects: 177

Group type: COMPARATOR
Intervention: Intermediate vs. High dose
Number of subjects: 177

Group type: COMPARATOR
Intervention: Low vs. High dose
Number of subjects: 177
Study: 3117477

Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise at 12 W with varying pedalling rates (30-50 cycles/min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise at 37 W with varying pedalling rates (30-50 cycles/min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Supine exercise at 12 W
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of males and females during exercise
Number of subjects: 15
Study: 2790695

Group type: EXPERIMENTAL
Intervention: Endocrine treatment plus five-drug chemotherapy (CMFVPT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Endocrine treatment (tamoxifen [T], 40 mg daily for 3 years)
Number of subjects: 94
Study: 30796973

Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia episodes
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: GAD-positive patients
Number of subjects: 98
Study: 31652010

Group type: EXPERIMENTAL
Intervention: Negative binomial distribution sample size calculation method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of slopes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of time-averaged responses
Number of subjects: 0
Study: 27557955

Group type: EXPERIMENTAL
Intervention: Multi-site infiltration analgesia (MIA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 77
Study: 26742306

Group type: EXPERIMENTAL
Intervention: Aloe vera syrup (10 mL/d, standardized to 5.0 mg polysaccharide per mL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Omeprazole capsule (20 g/d)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ranitidine tablet (150 mg in a fasted state in the morning and 150 mg 30 min before sleep at night)
Number of subjects: 79
Study: 23825422

Group type: EXPERIMENTAL
Intervention: Top-down expectation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional precision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit top-down expectation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drift of the CNV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus predictability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 21707983

Group type: EXPERIMENTAL
Intervention: IV nicardipine
Number of subjects: 226

Group type: COMPARATOR
Intervention: IV labetalol
Number of subjects: 226
Study: 19743936

Group type: EXPERIMENTAL
Intervention: 2.5% chitin‐glucan formulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glycerol formulations
Number of subjects: 30
Study: 16500394

Group type: EXPERIMENTAL
Intervention: Internet interface for assessment of endoscopic still images
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Internet interface for assessment of video clips from DVDs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-quality video assessment
Number of subjects: 4
Study: 16061111

Group type: EXPERIMENTAL
Intervention: Amoxicillin-sulbactam (Ax/S) at a dosage of 80 mg/(kg day), b.i.d. for 10 days
Number of subjects: 289

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (Ax/C) at a dosage of 80 mg/(kg day), b.i.d. for 10 days
Number of subjects: 289
Study: 11341427

Group type: EXPERIMENTAL
Intervention: Randomised, controlled trials with inadequate sample sizes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Average sample size used in studies
Number of subjects: 33
Study: 9762567

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin produced and formulated in the People's Republic of China
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin produced in Vietnam but formulated by the Government Pharmaceutical Organization of Thailand
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin produced and formulated by the Government Pharmaceutical Organization of Thailand
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 133
Study: 7871074

Group type: EXPERIMENTAL
Intervention: Alcohol alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Marijuana alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alcohol and marijuana in combination
Number of subjects: 14

Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 14
Study: 3060430

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol with Indomethacin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 10
Study: 31425359

Group type: EXPERIMENTAL
Intervention: Jaw thrust test
Number of subjects: 30
Study: 28493943

Group type: EXPERIMENTAL
Intervention: Open Lung Approach (OLA) with individualized PEEP (8±2 cmH2O)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard PEEP of 5 cmH2O (RM-5 group)
Number of subjects: 36
Study: 25947566

Group type: EXPERIMENTAL
Intervention: Elisidepsin (PM02734) administered as a 30-min intravenous infusion every 3 weeks (q3wk) at doses ranging from 0.1 to 1.6 mg/m(2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Elisidepsin (PM02734) administered as a 3-hour intravenous infusion every 3 weeks (q3wk) at doses ranging from 2.0 to 11.0 mg flat dose (FD)
Number of subjects: 53
Study: 23595408

Group type: EXPERIMENTAL
Intervention: Upper quartile average of esophageal temperature
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Upper quartile average of skin temperature
Number of subjects: 106
Study: 21663994

Group type: COMPARATOR
Intervention: 4 weeks of guideline-based pulmonary rehabilitation (PR)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ten preoperative PR sessions using a customized protocol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study: 19919789

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (AP) administered 2 hours before incision and continued for 24 hours (Experimental Group, EG)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Traditional antibiotic scheme administered just before, during, or after incision and continued for 5 days (Control Group, CG)
Number of subjects: 171
Study: 17043614

Group type: EXPERIMENTAL
Intervention: Modified cold blood cardioplegia enriched with potassium‐magnesium aspartate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (routine institutional cold blood cardioplegia)
Number of subjects: 40
Study: 12759292

Group type: EXPERIMENTAL
Intervention: Total direct costs for RA patients
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: RA related direct costs
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Outpatient costs
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Inpatient costs
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Other disease related costs
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Cost drivers for outpatients
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Costs incurred by prematurely retired patients
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Costs incurred by gainfully employed patients
Number of subjects: 338
Study: 11530117

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (80 U/500 mL) infused at 2667 mU/min
Number of subjects: 321

Group type: COMPARATOR
Intervention: Low-dose oxytocin (10 U/500 mL) infused at 333 mU/min
Number of subjects: 321

Group type: COMPARATOR
Intervention: Low-dose oxytocin (10 U/500 mL)
Number of subjects: 321
Study: 9249230

Group type: EXPERIMENTAL
Intervention: Low sodium diet plus sodium tablets (80 mmols/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low sodium diet plus placebo tablets
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 17
Study: 7506167

Group type: EXPERIMENTAL
Intervention: nimesulide 100mg twice daily for 8 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 3545674

Group type: EXPERIMENTAL
Intervention: Heparin concentration of 5 U/ml
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Heparin flow rate of 2 ml/h
Number of subjects: 470

Group type: COMPARATOR
Intervention: Heparin flow rate of 1 ml/h
Number of subjects: 470